RecruitingPhase 1Phase 2NCT06853015

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury

Sponsor

Shirley Ryan AbilityLab

Enrollment

27 participants

Start Date

Feb 1, 2025

Study Type

INTERVENTIONAL

Conditions

SCI - Spinal Cord Injury

Summary

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dalfampridine, a behavioral approach called Exercise training, and others for people with sci - spinal cord injury. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDalfampridine

The study drug (4-AP) will be administered as a 10 mg dose twice a day.

DRUGPlacebo

The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.

OTHERSTDP stimulation

Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.

BEHAVIORALExercise training

Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.